Clinical study for treatment effect of HP for patients with rheumatic disease and latent tuberculosis infection.

Treatment effect of HP for patients with rheumatic disease and latent tuberculosis infection.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025011

Enrollment

Unknown

Registered

2019-08-07

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent TB infection

Interventions

3 HP Group:HP for 3 months

1HP Group:HP for 1 month

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with rheumatic immune diseases and latent tuberculosis infection; 2. Aged 18 to 65 years, male or female, including inpatient and outpatients.

Exclusion criteria

Exclusion criteria: 1. Latent TB patients who are in close contact with MDR-TB; 2. Severe comorbidities or impaired renal function (1.5 times the serum creatinine above the upper limit of normal) or impaired liver function (2.5 times the ALT and/or AST level above the upper limit); 3. Active tuberculosis patients; 4. HIV-positive or AIDS patients. 5. Serious cardiovascular diseases such as heart failure, high blood pressure (poor blood pressure control), arrhythmia or post-myocardial infarction state.

Design outcomes

Primary

Measure	Time frame
incident rate of active TB;	—

Secondary

Measure	Time frame
completion rate;	—

Countries

China

Contacts

Public ContactGuofang Deng

The Third People's Hospital of Shenzhen

jxxk1035@yeah.net+86 13530027001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026